MET and hepatocellular carcinoma: High-level MET amp may be an oncogenic driver in HCC that sensitizes tumors to MET inhibition with tepotinib. Compared with MET overexpression, high-level MET amp could be a better predictive biomarker for MET inhibitors in this setting